www.fdanews.com/articles/100697-takeda-8217-s-tak-442-enters-phase-ii-development
Takeda’s TAK-442 Enters Phase II Development
November 6, 2007
Japan drugmaker Takeda Pharmaceutical’s investigational compound TAK-442 has entered Phase II studies in the U.S. and Europe.
TAK-442 is a novel Factor Xa inhibitor developed by Takeda.
Factor Xa (FXa) plays a role in the blood coagulation cascade. Inhibition of FXa is expected to result in interruption of either venous or arterial thromboembolism, Takeda said.